期刊文献+

坎地沙坦辅助治疗慢性充血性心力衰竭的临床疗效观察 被引量:3

下载PDF
导出
摘要 目的探讨研究坎地沙坦片对慢性心力衰竭的临床疗效。方法选取我院2007年3月至2009年5月收治的98例慢性心力衰竭患者,随机分为治疗组和对照组,对照组应用血管紧张素转换酶抑制剂,醛固酮拮抗剂、β受体阻断剂和洋地黄类药物治疗,治疗组除了应用对照组所用的药物之外加用坎地沙坦酯片(8mg/d)治疗,治疗时间为4周,治疗结束后比较两组患者治疗前后左室射血分数(LVEF)、每搏量(SV)、左室舒张末内径(LVDD)、每分心排血量(CO)。结果经过4周的治疗,治疗组患者的左室舒张末内径(LVDD)减小(P<0.05),左室射血分数(LVEF)增加(P<0.05),与对照组患者相比差异有统计学意义。结论慢性充血性心力衰竭患者在常规治疗的基础上加用坎地沙坦能够更好的改善心力衰竭患者的心脏功能,在临床上值得推广。
作者 范军
出处 《中国现代药物应用》 2010年第20期87-88,共2页 Chinese Journal of Modern Drug Application
  • 相关文献

参考文献2

二级参考文献4

  • 1Mc clellan KJ,Goa KL.Candesartan cilexetil.A review of its use in essential hypertension[J].Drug,1998,56(5):847.
  • 2Yoshiyama M,Omura T,Yoshikawa J.Additive improvement of left ventricular remodeling by aldosterone receptor blockade with eplerenone and angiotensin Ⅱ type Ⅰ receptor antagonist in rats with myocardial anfarction[J].Nippon Yakurigaku Zasshi,2004,124(2):83.
  • 3Yasumura Y,Miyatake K,Okamoto H,et al.Rationale for the use of combination angiotensin-converting enzyme inhibitor and angiotensin Ⅱreceptor blockade therapy in heart failure[J].Circ J,2004,68(4):361.
  • 4Shinohara H,Fukuda N,Soeki T,et al.Effects of angiotensin Ⅱ receptor antagonists on[(123)] metaiodobenzy(1)guanidine myocardial imaging findings and neurohumoral factors in chronic heart failure[J].Heart Vessels.2002.17 (2):47.

共引文献309

同被引文献33

  • 1赵玉生,李佳月,吴海云,李泱,林海丽,王士雯.老年充血性心力衰竭住院患者不同年龄段病因、诱因和病死率调查[J].中华老年多器官疾病杂志,2007,6(3):153-155. 被引量:23
  • 2Yoshimura M, Yasue H.Hemodynamic and hormonal effects of the angiotensin II antagonist, candesartan cilexetil, in patients with congestive heart failure[J].Cardiology, 2000;93(3):175~182.
  • 3Mckelvie RS, Rouleau JL, White M, et al.eomparative impact of enalapril, candesartan or metoprolol alone or in combination on ventricular remodelling in patients with congestive heart failure[J].European Heart Journal, 2003;24(19):1727-1734.
  • 4赵彩梅.坎地沙坦对充血性心力衰竭(CHF)的治疗效果和药理分析[I].中国农村卫生,2012:z2:271~272.
  • 5Onishi K, Dohi K, Koji T, et al. Candesartan prevents myocardial fibrosis during progression of congestive heart failure[J].Journal of Cardiovascular Pharmacology, 2004;43(6):860~867.
  • 6Alehagen U,Dahlstrom U,Rehfeld JLAssociation of copeptin and N-terminal proBNP conceiatrations with risk of car-diovascular death in older patients with symptoms of heart failure[J].JAMA, 2011,305 (20) : 2088-2095.
  • 7Miller WL, Hartman KA, Grill DE,et a/.Serial measurements of midregion proANP and copeptin in ambulatory patients with heart failure:incremental prognostic value of novel biomarkers in heart failure[J].Heart, 2012,98 (5) : 389-394.
  • 8Masson S,Latini R,Carbonieri E,et a/.The predictive val- ue of stable precursor fragments of vasoactive peptides in patients with chronic heart failure:data from the GISSI- heart failure(GISSI-HF) trial[J].Eur J Heart Fail,2010, 12 (4) : 338-347.
  • 9Tentzeris L, Jarai R,Farhan S,et a/.Complementary role of copeptin and high-sensitivity troponin in predicting out- come in patients with stable chronic heart failure[J].Eur J Heart Fail,2011,13(7) :726-733.
  • 10Narayan H, Dhillon OS, QUINN PA,et a/.C-terminal prova- sopressin(copeptin) as a prognostic marker after acute non- ST elevation myocardial infarction: Leicester Acute My- ocardial Infarction Peptide I1 (LAMP 11 ) study[J].Clin Sci (Lond), 2011,121 (2) :79-89.

引证文献3

二级引证文献7

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部